Technical University of Munich – Institute of Virology / Adoptive T-cell therapy group
STANDARD OPERATING PROCEDURE FOR:
RETROVIRAL TRANSDUCTION OF HUMAN T-CELLS
1. Material
Producer cell line / or ready-to-use virus supernatant
Isolated human PBMC blood cells
Neubauer improved counting chamber, or chamber for NucleoCounter NC-250
Variable micropipettes
Plastic pipettes (2mL, 5mL, 10mL, 25mL)
50mL tubes
Non-tissue-coated well plates
Sterile syringes and needles for blood collection (20G)
V-bottom plate (for FACS coloring)
0.45µm filters
2. Reagents & Solutions
Transfection reagent – Lipofectamine 2000
OptiMEM
RetroNectin
Sterile 2% BSA
IL-2 (Peprotech solution Stock 100 000U/ml)
Anti-human CD3 and CD28 antibodies for stimulation of human T cells
EtOH 70% (for disinfection)
DMEM full medium (10%FCS, 1%P/S, 1%L-Glutamin, 1%So-Pyruvat, 1%NEAA)
Human T cell Medium (10% FCS or HS, 1% Penicillin/Streptomycin (P/S), 1% L-Glutamine, 1% Sodium-Pyruvate, 1% NEAA, 1% HEPES, 208µL Gentamicin = 0,04%)
Wash medium (RPMI + 1%P/S)
Trypan blue or AO-DAPI staining reagent (live/dead staining)
PBS (1x solution)
FACS buffer (PBS 1x + 10%FCS or 0,1%BSA)
Specific antibodies for FACS coloring
Pancoll human (1,077g/mL), Gradient solution for PMBC isolation
3. Instruments
Centrifuge (for Falcon tubes and tissue plates)
Sterile workbench
CO2 Incubator
Water bath (37°C)
Pipettes
Microscope or Cell Counter
FACS machine (Cytoflex or comparable)
4. Medium, Supplements & Reagents
Product
company
Order number
more
DMEM
Gibco
11960-085
RPMI 1640
Gibco
21875-034
Penicillin/ Streptomycin
Gibco
15140-122
L-Glutamine
Gibco
25030-024
NEAA
Gibco
11140-035
Sodium Pyruvat
Gibco
11360-039
Trypan blue / DAPI (solution 18)
Gibco/ChemoMetec
15250-061 / 910-3018
Recombinant human IL-2
Peprotech/Thermo Fisher
200-02-50UG
Stock 100 000 U/ml
PBS (10x)
Gibco
70011-051
pH 7.4
BSA
Sigma
A2153-100G
RetroNectin
Takara
T100B
1µg/µL
OptiMEM
Gibco
31985-062
1x
Lipofectamine 2000
Thermo
11668-019
1mg/mL
Pancoll
PAN Biotech
P04-60500
1.077g/ml
FCS (HI)
Gibco
10500-064
Human Serum
self-made
Serum pool
-80°C
5. RetroNectin Coating
RetroNectin
Use non-tissue-coated plates
RetroNectin stock 1µg/µl
Prepare 1:50 solution in PBS (1x) from stock – can be used two times
Working solution concentration 20µg/ml
2 h incubation at RT; after that time remove the RetroNectin
Block with BSA 2% in PBS (1X), 30min at 37°C
Wash 2 x with PBS (1x)
Ready to use
6. RD114 Packaging cells Transfection (Monday)
Culture packaging cells (example: Friday to Monday, RD114 cells, 6-well plate - seed 1.25 x10E5 cells/ well in DMEM full medium; the optimal cell density for transfection is 60-80% confluency)
Transfection mix:
Tube 1 (1well)
Tube 2 (1well)
5µL Lipofectamine 2000
5µg TCR/CAR plasmid (15 µg for 10mm Petri Dishes)
125µL OptiMEM
125µL with OptiMEM
Finger-flick ~20 times each tube to mix the corresponding components
Incubate mix 1 and 2 separately for 5 min at RT
Pool tubes 1 and 2 and incubate for 20 min at RT (Transfection mix)
Add 260µl transfection mix/well of RD114 packaging cells
Incubate at 37°C for 48 hours (until day of 1st transduction hit)
7. Human PBMC Preparation (Monday)
Fresh cells
Recruit a blood donor (calculate 100mL blood, for around 100 x 10^6 PBMCs)
Human PBMC isolation:
Dilute whole blood 1:1 in RPMI wash medium (as soon as possible after blood collection)
Prepare 50 mL Falcon tubes with 12.5 mL Pancoll solution
Overlay Pancoll with 25ml of the blood solution
Centrifuge with 1000xg, 20min, w/o brake
Transfer PBMC stage into a new 50 mL Falcon
Fill up to 50ml with wash medium
Firstwash: 700xg, 10min, RT (remove supernatant)
Resuspend cell pellet in 40ml wash medium
Second wash: 350xg, 5min, RT
(optional) 70g, 20min, RT
Pool all tubes and resuspend the total cell pellet in 25ml human T-cell medium
Count the cells
Calculate cell amount necessary for transduction (usually 1-3 x 10E6 per TCR/CAR transduction)
Freeze the remaining cells for future experiments
CD3/CD28 activation with antibodies:
Coat a non-tissue well plate with human CD3 5µg/mL and human CD28 1µg/mL (in PBS)
Incubate overnight at 4°C or for 2 h at 37°C
Remove the antibody solution
Add 2% BSA in PBS
Incubate 30min, 37°C (Blocking)
Wash 1x with PBS (1x)
Ready to use
Plate freshly isolated PBMCs or thawed cryopreserved cells in a 6-well plate - 1x10E6 /mL plus 300U/mL IL-2
Incubate for 48 hours (until day of 1st transduction hit)
Cryopreserved cells
Thaw PBMCs in warm human T-cell medium
Count cells (with Neubauer improved chamber, NucleoCounter system or comparable)
Culture and stimulate the same as for freshly isolated PBMCs
8. 1st transduction hit (Wednesday)
Use RetroNectin-coated plate (described in section 5. COATING)
Virus supernatant
From the transfected packaging cells, harvest virus supernatant and filter it with a 0.45 µm filter into a sterile tube
(Supernatants from the same conditions -TCR or CAR plasmid- can be pooled)
Add 2mL fresh, warm DMEM full medium to the transfected packaging cells for further virus production, needed for the 2nd transduction hit (add the medium immediately after harvesting the supernatant to avoid the cell monolayer drying out)
From the harvested and filtered virus supernatant, distribute 2mL per RetroNectin-coated well
Centrifuge the RetroNectin plate containing the viral supernatant at 2000xg, 2h, 32°C (spinoculation)
In the last 30 minutes of the virus supernatant centrifugation, collect activated human PBMCs from the antibody-coated plate (CD3/CD28)
Count cells (with Neubauer improved chamber, NucleoCounter system, or comparable)
After spinoculation, remove the supernatant from the RetroNectin-coated plate (avoid the well from drying out)
Add T cell suspension to wells of the RetroNectin-coated plate (for a 24-well plate, add 1 x 10E6 cells in 1 mL T cell medium; for a 6-well plate, add 3-5 x 10E6 cells in 3 to 5 mL T cell medium)
Centrifuge at 1000xg, 10min, 32°C
Incubate for 24 hours at 37°C and 5% CO2
9. 2nd Transduction hit (Thursday)
RetroNectin coating of a 24-well non-tissue plate (procedure at protocol point 5- COATING)
From the transfected packaging cells, harvest virus supernatant and filter it with a 0.45 µm filter into a sterile tube
(Supernatants from the same conditions -TCR or CAR plasmid- can be pooled)
Dispose of plate with packaging cells
Distribute 2mL of the sterile filtered virus supernatant per RetroNectin-coated well
Centrifuge at 2000xg, 2h, 32°C (spinoculation)
After spinoculation, remove the supernatant from the RetroNectin-coated plate (avoid the well from drying out)
Transfer human PBMCs from the 1st transduction hit plate, well by well, to the newly prepared RetroNectin plate from step 5.
Centrifuge 1000xg, 10min, 32°C
Incubate overnight at 37°C and 5% CO2
10. Expansion of transduced cells (Friday)
Harvest transduced human T cells, one day after the 2nd transduction hit
Count cells
Culture cells in a new cell culture flask or culture plate with 0.5 -1.0 x 10 E6 cells/mL and 100U/mL IL2 in human T-cell medium to allow for cell expansion (avoid high cell densities per flask or well to allow proper expansion; also, avoid low densities since T cells grow better when in relatively close proximity).
11. Expansion and surface staining of transduced cells (Day 4 -Monday- after 2nd transduction hit)
Count the cells
Perform Flow cytometry surface staining (CD3, CD4, CD8, TCR, live/dead dye) to determine the transduction efficiency. An expression kinetic can be performed by staining every other day (for example, days 4, 7, 10, and 13 after the 2nd transduction hit) until the day of freezing.
During expansion (between day 4 and day 13 after the 2nd transduction hit), add fresh medium and adjust the IL-2 concentration to 100 U/ml every other day to maintain optimal T cell expansion culture conditions.
Normal expansion time for T cells is 10 to 13 days after the 2nd transduction hit; this allows the cells to expand and transition from their highly activated state.
After the expansion time is over (Day10 - Day13), transduced T cells can be used directly for functional assays or frozen for long-term storage @ -80°C or in a liquid Nitrogen tank.
Readers should cite both the Bio-protocol preprint and the original research article where this protocol was used:
Protzer, U(2026). 2.9. Retroviral transduction of T cells. Bio-protocol Preprint. 10.21769/p3027.
Schreiber, S., Dressler, L. S., Loffredo-Verde, E., Asen, T., Färber, S., Wang, W., Groll, T., Chakraborty, A., Kolbe, F., Kreer, C., Kosinska, A. D., Simon, S., Urban, S., Klein, F., Riddell, S. R. and Protzer, U.(2024). CARs derived from broadly neutralizing, human monoclonal antibodies identified by single B cell sorting target hepatitis B virus-positive cells. Frontiers in Immunology. DOI: 10.3389/fimmu.2024.1340619
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this
article to respond.
Post a Question
0 Q&A
Spinning
This protocol preprint was submitted via the "Request
a Protocol" track.